Press Release: Correction: Strong Trauma/LOQTEQ(R) sales growth in the first nine months of 2013

aap Implantate AG / Correction: Strong Trauma/LOQTEQ(R) sales growth in the first nine months of 2013 . Ad hoc announcement according to -- 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) increased its total sales by 3 % to EUR 28.4 million (previous year: EUR 27.5 million) in the first nine months of 2013. EBITDA at EUR 5.3 million (previous year: EUR 4.8 million), was up by 11 % year on year.

In EUR million 9m/2013 9m/2012 Change Sales 28.4 27.5 3% EBITDA 5.3 4.8 11% Cash-EBITDA 3.8 2.5 53% Cash-EBT 2.4 0.8 >100%

In EUR million Q3/2013 Q3/2012 Change Sales 8.8 8.6 2% EBITDA 1.1 1.2 -12% Cash-EBITDA 0.7 0.4 68% Cash-EBT 0.2 -0.2 >100%

In the first nine months and the third quarter, we achieved the following highlights:

-- Trauma sales (incl. LOQTEQ(R)) in the third quarter increased 50% to EUR2.2 million (previous year: EUR1.5 million) and increased 63% to EUR6.5 million in the first nine months (previous year: EUR4.0 million)

-- LOQTEQ(R) sales increased by EUR0.5 million to EUR1.1 million (+83%) in the third quarter of 2013 (previous year: EUR0.6 million) and by 182% to EUR3.1 million in the first nine months (previous year: EUR1.1 million)

-- Turnover rate of Working capital (based on last four quarter sales) improved from 2.25 (30.9.2012) to 2.31 (+3%)

-- Net debt (interest bearing) reduction from EUR4.3 million (31.12.2012) to EUR3.0 million

-- Intangible assets percentage (as of the balance sheet total) reduction from 57% (31.12.2012) to 52%

Given the importance of the LOQTEQ(R) product family and our focus on the Trauma market, we would like to highlight the following activities:

-- Signing a new distribution agreement for LOQTEQ(R) with an Saudi Arabian distributor, first supply will be shipped in the fourth quarter 2013

-- Delivering the first supply of LOQTEQ(R) products to our distributor in Bulgaria

-- Receiving CE-approval for four of the six new LOQTEQ(R) plating systems (phase 2), two of them already received FDA-approval.

-- Continuing the LOQTEQ(R) post marketing study, with initial reports demonstrating very promising fracture repair qualities and ease of use, including no reported cases of cold welding

Outlook 2013

For the fourth quarter of 2013, the management board forecasts sales in the range of EUR10.5 million to EUR11.6 million and an EBITDA of EUR1.3 million to EUR1.7 million. Sales and profitability will be mainly driven by sales of trauma products, especially LOQTEQ(R), and as previously announced, bone cement and cementing devices.

The Outlook for the fourth quarter 2013 supports the reconfirmation of the full year forecast of sales growth of 10% to approx. EUR40 million and an EBITDA growth of approx. 15% to EUR7 million.

The evaluation process of the strategic options for EMCM is ongoing.

aap Implantate AG's full Q3 2013 report is available to download at www.aap.de.

______________________________________________________

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: aap Implantate AG via Thomson Reuters ONE

HUG#1742182

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

www.aap.de (END) Dow Jones Newswires

   November 11, 2013 09:10 ET (14:10 GMT)- - 09 10 AM EST 11-11-13